On June 1, hosted by Shanghai Modern Biology and Pharmaceutical Industry Office, prepared by YRPG and Shanghai Bio-medicine Technology Promotion Center and Shanghai Technology Convention and Exhibition Co., Ltd., the 13^th Bio-Forum & YRPG Biological Preparation Forum was held in Shanghai Expo Center.
Chen Kehong,General Secretary of Shanghai Commission of Science and Technology, Tang Minhao,Deputy Director of Shanghai Food and Drug Administration, andXu Jingren,Chairman and General Manager of YRPG,addressedthe forum. Six experts at bio-medicine field at home and abroad, including Zhao Guoping,Academician of Chinese Academy of Sciences, Dave Tapolczay,President of Technology Department of Medical Research Council Technology, and Joseph Panetta,President of Biocom, made academic reports on the trend of bio-pharmacy and research and development of new medicines, and held extensive communication and discussion. The experts also held a seminar on the research and development of bio-pharmacy in YRPG. Ninecooperated research and development projects on the forum including protein drug, peptide drugs, small-molecule DNA, receptor-targeted peptide drug were introduced and published.
This is the 40^th anniversary of YRPG. Since itsbirth, YRPG has been stickingto the philosophyof "Seeking progress all the time and safeguardinghealth for all human beings",and "Benefiting the public through innovation and quality products". It has beendedicated to the innovative research and development of traditional Chinese medicines, chemical drugs, biological drugs, and thus the comprehensive economic profits have ascended to top 5 among national pharmaceutical industry for over 10 consecutiveyears. In recent years, YRPG has reinforced the research and development of new medicines with independent intellectual property rights. Over 30 domestic and foreign doctors workedthe new medicine research institute. YRPG established research centers such as national key new technology laboratory of Chinese medicine, chemical medicine, bio-medicine and Chinese medical preparation. With the aid of innovative platforms such as national-level enterprise technology center, post-doctoral research center, academician center, and national engineering research center for Chinese medicine preparation technology, YRPG’s achievements in scientific research were flourishing. Duringthe 11th Five-year plan, YRPG has completed 65 new medicine projects in total, in which there are 26 innovative medicines, applied for 56 patents for inventions, of which 18 patents for inventions wereauthorized, and applied 8 international patents for inventions, 44 industrial standards of various products and27 new products achievementscommercialized by the research institute. The proportion of sales of new products in those of YRPG increases to 50%. The star product developed by the research institute-comforting particle before menstrual period won the second prize of national science and technology progress award, the first prize of China Association of Chinese Medicine, national patent for invention award of excellence. The exclusive medicinesound sleep capsule won the special gold medal for national patent for invention. YRPG was granted the first group of “innovative enterprises” by the Ministry of Science and Technology of the People’s Republic of China, State-owned Assets Supervision and Administration Commission of the State Council and All China Federation of Trade Unions.
Xu Jingren said that when enforcing the simultaneous research and development strategy of Chinese medicine, chemical medicines and bio-medicine, YRPG would shift to bio-pharmaceuticals in the future. He hoped YRPG couldfurther extend the vision, aim at international front, keep informed of the latest progress and development trend of the bio-medicines, attract talents from all around the world, seek cooperation opportunities, expanding bio-medicine and making YRPG the first-rate pharmaceutical enterprise with international competition.